Medicine
Zioptan 0.015 mg/mL eye drops
Zioptan 0.015 mg/mL eye drops is a prescription medicine containing Tafluprost for ophthalmic use, marketed by Thea Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 2° to 8°C (36° to 46°F). During shipment ZIOPTAN may be…
Key facts
- Active ingredient (INN)
- Tafluprost
- Brand
- Zioptan
- Strength
- 0.015 mg/mL
- Dosage form
- Eye drops
- Route
- Ophthalmic
- Packs
- 3 pouches
- Marketing authorisation holder
- Thea Pharma
- Manufacturer
- Thea Pharma
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 2° to 8°C (36° to 46°F). During shipment ZIOPTAN may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 2 days. After the pouch is opened, unopened single-dose containers may be stored in the opened foil pouch for up to 30 days at room temperature 20° to 25°C (68° to 77°F). Store in the original pouch. Protect from moisture.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- S01EE05 Tafluprost
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 October 2022
- Identifiers
- RxCUI 1244611, 1244616DailyMed set ID db529b54-2ac7-4020-9791-7333bbe6c90fNDC 82584-609Application NDA202514
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 3 pouch in 1 carton / 10 vial, single-use in 1 pouch / .3 mL in 1 vial, single-use | 82584-609-30 | Thea Pharma | 28 October 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 10 February 2012 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Tafluprost
Clinical summary
Tafluprost is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is available as eye drops for ophthalmic use. MedsAcross supplies Tafluprost for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TafluprostFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZIOPTAN prescribing information (Thea Pharma) · U.S. National Library of Medicine, DailyMed
Need Zioptan 0.015 mg/mL eye drops for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.